Actively Recruiting
The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children
Led by University Hospital, Strasbourg, France · Updated on 2024-07-12
151
Participants Needed
1
Research Sites
78 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences. The research hypothesis is that LEVETIRACETAM is non-inferior to PHENYTOIN in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus
CONDITIONS
Official Title
The "New" Place of LEVETIRACETAM in the Management of Status Epilepticus in Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Child aged 3 months to 17 years
- Received levetiracetam or phenytoin as second-line treatment after benzodiazepines
- Treated at a participating center between November 1, 2019 and May 31, 2023
- No opposition by the child or parents to reuse of medical data for research
You will not qualify if you...
- Child or parents have expressed opposition to participation in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service pédiatrie 1 - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
S
Sarah BAER, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here